Article
The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.
The Journal of international medical research - 1 May 2022
He Shujiao, Zhang Minjie, Li Jieying, Zhao Weiqiang, Yu Li, Han Ying, Pang Yanbin
Abstract excerpt
A Y842D mutation within the activation loop of fms-like tyrosine kinase 3 (FLT3) has been shown to confer strong resistance to sorafenib in vitro. Whether this type of mutation exerts clinically significant effects in patients with acute myeloid leukaemia (AML) remains unclear. Here, a novel Y842D activating mutation within the kinase domain of FLT3, in a pregnant patient with de novo hyperleucocyte acute myeloid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.